Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease. - Wikidata - awgldk - TriplyDB

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

http://www.wikidata.org/entity/Q33713069

about

Regenerative Medicine: Charting a New Course in Wound Healing A Current View of Functional Biomaterials for Wound Care, Molecular and Cellular Therapies Gene therapy for skin diseases Platelet-Rich Fibrin Lysate Can Ameliorate Dysfunction of Chronically UVA-Irradiated Human Dermal Fibroblasts.Clinical application of growth factors and cytokines in wound healing Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.Epidemiology and aetiology of C4-6 disease.PDGF and the progression of renal disease.Effect of sustained PDGF nonviral gene delivery on repair of tooth-supporting bone defects Human Tissue Inhibitor of Metalloproteinases-1 Improved Wound Healing in Diabetes through Its Anti-apoptotic Effect.

P2860

Q26745626-4F03D646-3934-4D61-B5EC-7E3546D2D3F2 Q26778235-A05A9546-0CD1-4FA4-B39C-F67793F63B38 Q26994703-B350C991-B2B5-4036-84BD-BF7092A2F959 Q36073184-874EDBC6-8798-49FF-A2A0-F970F22566FD Q36742273-DB1FD39F-0979-46B0-85C2-D1B389CB9450 Q37712686-3A834513-EB23-4E32-B8BF-7757259D15C5 Q37792660-0D527715-80F2-49A5-A503-A89B90A37B32 Q38185014-C6D51260-4204-4C9B-8068-1694C7E99212 Q42327817-233B866C-E53E-4040-9A4C-C272B419253A Q45871696-FEF317BE-6A2A-4E0F-938E-31781CD2D56C

P2860

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

http://www.wikidata.org/entity/Q33713069

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@ast

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@en

type

label

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@ast

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@en

prefLabel

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@ast

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@en

P1433

Q33713069-05393D87-10B3-4407-8A17-1FAC0B58E7CC

P1476

Q33713069-9D57CF29-090F-4D0F-8CA5-022E33A0BB51

P2093

Q33713069-32107E5C-422B-457D-AB64-18F75ABBCE40

Q33713069-3631ED10-A059-49D7-A080-51982C886283

Q33713069-3938F376-1515-4144-9258-F4AC38D6122D

Q33713069-4654DB5C-651C-4F85-AEE0-56118256E1B6

Q33713069-750D4D73-E3D7-48D1-9046-BBB9BA80301D

Q33713069-AB9E493C-2AAB-4D1B-94CB-545A064545FD

Q33713069-BF14A5E4-E622-41FD-A7D8-0A2533B15719

Q33713069-D3FD36B0-82CC-4522-B3B6-B967A558DDFB

P2860

Q33713069-19FBE46F-0D4B-4811-8228-B6A93C2843F5

Q33713069-1C33FF77-C935-4C0B-A5DA-676E591F7054

Q33713069-1D75884F-BEC1-4D6D-9D49-D8031172E043

Q33713069-20D343C8-CCC0-488A-8FF8-7254F9DC6ADF

Q33713069-2208DE5F-99D3-42B4-9C6E-FEB38C2C37BE

Q33713069-2CD33294-D668-4826-9E90-7D55F18B9224

Q33713069-4B2E46E1-905A-4F55-B3AB-C110C4A2E367

Q33713069-4F79C09D-0737-4805-8122-80CE8A983963

Q33713069-5C329029-F57A-44FC-ACBF-9498C44D2E85

Q33713069-61D13543-E70F-4974-B92D-48C57D4EEF35

P304

Q33713069-EBA09622-79D5-43D7-A822-F05E1864FA56

P31

Q33713069-D6E48EE6-9955-41DA-B07F-DA8237B62116

P356

Q33713069-F013D1A0-13E7-4C89-B851-65A93D38099C

P433

Q33713069-47186B84-7386-4AB2-9E6B-9616F26B9447

P478

Q33713069-26FA9E50-8258-4560-BFE5-992B783F3400

P577

Q33713069-2BA8A987-3E20-4571-9603-1D9FA49B5072

P5875

Q33713069-4ED6D0B4-B19A-46CD-90AC-7DE320E4541A

P698

Q33713069-CD067641-AEFC-4712-90FF-D1640F746190

P932

Q33713069-52822772-9AFF-4FBD-B918-81727F3A23E1

P356

P1433

Molecular Therapy

P1476

Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

@en

P2093

David J Margolis

http://www.w3.org/2001/XMLSchema#string

Jennifer C Filip

http://www.w3.org/2001/XMLSchema#string

Lee M Morris

http://www.w3.org/2001/XMLSchema#string

Linda Weinberg

http://www.w3.org/2001/XMLSchema#string

Maryte Papadopoulos

http://www.w3.org/2001/XMLSchema#string

Sachin S Vaikunth

http://www.w3.org/2001/XMLSchema#string

Stephanie A Lang

http://www.w3.org/2001/XMLSchema#string

Timothy M Crombleholme

http://www.w3.org/2001/XMLSchema#string

P2860

Origins of circulating endothelial cells and endothelial outgrowth from blood

CD133: molecule of the moment

Wound healing--aiming for perfect skin regeneration

Adenoviral-mediated gene transfer in wound healing.

Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.

Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor.

Reducing the incidence of foot ulceration and amputation in diabetes.

The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology.

Pharmacologic enhancement of wound healing.

Chronic cutaneous ulcers: etiology and epidemiology.

P304

1822-1829

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.169

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26701841

http://www.w3.org/2001/XMLSchema#string

P698

19638959

http://www.w3.org/2001/XMLSchema#string

P932

2835007

http://www.w3.org/2001/XMLSchema#string